Transfer of vitiligo after allogeneic bone marrow transplantation.
Adoptive transfer of donor immunity has been demonstrated in animals after bone marrow transplantation (BMT). In humans, several autoimmune diseases have been similarly transferred. Although BMT may, per se, be associated with a modulation of the recipient's immune system, which could trigger or even cause autoimmune diseases, both animal experiments and experience with humans show the likeliness of adoptive transfer of donor immunity to the recipient. We describe a patient with multiple myeloma in whom generalized vitiligo developed within 3 months after allogeneic BMT from his HLA-matched sister with vitiligo. We believe that a form of adoptive transfer of donor immunity to the recipient might play a role in the development of vitiligo. In spite of this, neither de novo development of vitiligo in a genetically predisposed patient nor autoimmune phenomena associated with graft-versus-host disease can be completely excluded as a contributing factor for development of vitiligo in our patient. To our knowledge, this is the first case report of transfer of vitiligo after BMT from a donor with vitiligo.
Alajlan
Abdulmajeed
A
Section of Dermatology, Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Alfadley
Abdullah
A
Pedersen
Kristian-Thestrup
KT
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology; D006801:Humans; D007116:Immunization, Passive; D019520:Living Donors; D008297:Male; D009101:Multiple Myeloma / Q000628:therapy*; D014820:Vitiligo / Q000209:etiology* / Q000276:immunology